{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:18:25Z","timestamp":1792293505213,"version":"4.4.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ctrv.2025.102971","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:55:28Z","timestamp":1748260528000},"page":"102971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma"],"prefix":"10.1016","volume":"139","author":[{"given":"Elizabeth C.","family":"Smyth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Mee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev A.","family":"Wainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayden","family":"Honeycutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Sommermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2025.102971_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102971_b0010","first-page":"26","article-title":"Epidemiology of gastric cancer: global trends, risk factors and prevention","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz Gastroenterol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102971_b0015","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/CMR.00011-10","article-title":"Helicobacter pylori and gastric cancer: factors that modulate disease risk","volume":"23","author":"Wroblewski","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102971_b0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4143\/crt.2024.253","article-title":"Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2021","volume":"56","author":"Park","year":"2024","journal-title":"Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102971_b0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/0284186X.2018.1546058","article-title":"Gastric cancer trends in Estonia 1995\u20132014 by age, subsite, morphology and stage","volume":"58","author":"P\u00e4rn","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2025.102971_b0030","unstructured":"American Cancer Society. Stomach Cancer Statistics, https:\/\/cancerstatisticscenter.cancer.org\/types\/stomach; 2024 [accessed February 12, 2025]."},{"key":"10.1016\/j.ctrv.2025.102971_b0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification","volume":"64","author":"Lauren","year":"1965","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102971_b0040","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"7517","key":"10.1016\/j.ctrv.2025.102971_b0045","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102971_b0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.102971_b0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.21037\/tgh.2020.03.07","article-title":"Impediments to therapeutic advances for patients with gastroesophageal adenocarcinoma","volume":"6","author":"Ajani","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102971_b0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5230\/jgc.2023.23.e11","article-title":"Korean Practice Guidelines for Gastric Cancer 2022: an evidence-based, multidisciplinary approach","volume":"23","author":"Kim","year":"2023","journal-title":"J Gastric Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102971_b0065","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102971_b0070","unstructured":"Lordick F, Smyth EC. ESMO Gastric Cancer Living Guideline, v1.3 June 2024, https:\/\/www.esmo.org\/living-guidelines\/esmo-gastric-cancer-living-guideline 2024 [accessed June 27, 2024]."},{"issue":"7","key":"10.1016\/j.ctrv.2025.102971_b0075","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.22.02331","article-title":"Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9742","key":"10.1016\/j.ctrv.2025.102971_b0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102971_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2019","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2025.102971_b0090","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"issue":"10294","key":"10.1016\/j.ctrv.2025.102971_b0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"7903","key":"10.1016\/j.ctrv.2025.102971_b0100","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.ctrv.2025.102971_b0105","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJMc2408121","article-title":"Pembrolizumab in HER2-positive gastric cancer","volume":"391","author":"Janjigian","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102971_b0110","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nature Med"},{"issue":"10389","key":"10.1016\/j.ctrv.2025.102971_b0115","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.102971_b0120","article-title":"Claudin 18.2 as a new biomarker in gastric cancer\u2014what should we know?","volume":"16(3):679","author":"Mathias-Machado","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2025.102971_b0125","unstructured":"US Food & Drug Administration. FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma; 2024 [accessed February 10, 2025]."},{"key":"10.1016\/j.ctrv.2025.102971_b0130","unstructured":"European Medicine Agency. Vyloy, Zolbetuximab, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyloy; 2024 [accessed February 10, 2025]."},{"key":"10.1016\/j.ctrv.2025.102971_b0135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2021.39.3_suppl.244","article-title":"The interaction between microsatellite instability high (MSI-high) gastric cancer and chemotherapy on survival","volume":"39","author":"Vos","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102971_b0140","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2025.102971_b0145","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10120-021-01195-4","article-title":"Optimized PD-L1 scoring of gastric cancer","volume":"24","author":"Schoemig-Markiefka","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2025.102971_b0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejca.2022.06.025","article-title":"Microsatellite instability and sex differences in resectable gastric cancer - a pooled analysis of three European cohorts","volume":"173","author":"Quaas","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102971_b0155","first-page":"28","article-title":"Microsatellite instability status in gastric cancer: a reappraisal of its clinical significance and relationship with mucin phenotypes. Korean","volume":"47","author":"Kim","year":"2013","journal-title":"JPathol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102971_b0160","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1093\/annonc\/mds104","article-title":"Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis","volume":"23","author":"Janjigian","year":"2012","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102971_b0165","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/jpm11111095","article-title":"Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas","volume":"11","author":"Pellino","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.ctrv.2025.102971_b0170","article-title":"Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 trial","volume":"9","author":"Rha","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102971_b0175","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2741\/4609","article-title":"Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells","volume":"23","author":"Ishiwata","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102971_b0180","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/annonc\/mdx081","article-title":"Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?","volume":"28","author":"Hierro","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102971_b0185","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ctrv.2025.102971_b0190","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102971_b0195","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102971_b0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/1477-3163.182809","article-title":"The well-accepted notion that gene amplification contributes to increased expression still remains, after all these years, a reasonable but unproven assumption","volume":"15","author":"Jia","year":"2016","journal-title":"J Carcinog"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102971_b0205","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102971_b0210","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102971_b0215","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102971_b0220","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1074\/jbc.M116.755777","article-title":"A new method to study heterodimerization of membrane proteins and its application to fibroblast growth factor receptors","volume":"292","author":"Del Piccolo","year":"2017","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102971_b0225","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"10.1016\/j.ctrv.2025.102971_b0230","doi-asserted-by":"crossref","first-page":"15694","DOI":"10.1074\/jbc.M601252200","article-title":"Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family","volume":"281","author":"Zhang","year":"2006","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102971_b0235","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.molcel.2013.08.002","article-title":"Functional proteomics defines the molecular switch underlying FGF receptor trafficking and cellular outputs","volume":"51","author":"Francavilla","year":"2013","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102971_b0240","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102971_b0245","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10120-021-01235-z","article-title":"The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration","volume":"24","author":"Ooki","year":"2021","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102971_b0250","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1159\/000494590","article-title":"FGFR2 promotes gastric cancer progression by inhibiting the expression of thrombospondin4 via PI3K-Akt-Mtor pathway","volume":"50","author":"Huang","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102971_b0255","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00018-022-04327-w","article-title":"Fgfr2b signaling is essential for the maintenance of the alveolar epithelial type 2 lineage during lung homeostasis in mice","volume":"79","author":"Ahmadvand","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102971_b0260","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/iovs.64.1.21","article-title":"Role of FGF10\/FGFR2b signaling in homeostasis and regeneration of adult lacrimal gland and corneal epithelium proliferation","volume":"64","author":"Finburgh","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"21","key":"10.1016\/j.ctrv.2025.102971_b0265","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1200\/JCO.19.01834","article-title":"Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma","volume":"38","author":"Catenacci","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102971_b0270","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1038\/s41598-021-84107-x","article-title":"Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer","volume":"11","author":"Yashiro","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102971_b0275","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10120-014-0444-1","article-title":"Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells","volume":"19","author":"Grygielewicz","year":"2016","journal-title":"Gastric Cancer"},{"issue":"23","key":"10.1016\/j.ctrv.2025.102971_b0280","doi-asserted-by":"crossref","first-page":"11271","DOI":"10.1158\/0008-5472.CAN-06-2044","article-title":"Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2","volume":"66","author":"Chaffer","year":"2006","journal-title":"Cancer Res"},{"issue":"38","key":"10.1016\/j.ctrv.2025.102971_b0285","doi-asserted-by":"crossref","first-page":"14116","DOI":"10.1073\/pnas.0603090103","article-title":"Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity","volume":"103","author":"Oltean","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102971_b0290","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102971_b0295","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/modpathol.2016.96","article-title":"FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival","volume":"29","author":"Ahn","year":"2016","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102971_b0300","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000441149","article-title":"Evaluation of fibroblast growth factor receptor 2 expression, heterogeneity and clinical significance in gastric cancer","volume":"82","author":"Han","year":"2015","journal-title":"Pathobiology"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102971_b0305","first-page":"1373","article-title":"Immunohistochemical detection of K-sam protein in stomach cancer","volume":"2","author":"Hattori","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102971_b0310","first-page":"307","article-title":"Expression of keratinocyte growth factor receptor correlates with expansive growth and early stage of gastric cancer","volume":"28","author":"Matsunobu","year":"2006","journal-title":"Int J Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102971_b0315","first-page":"875","article-title":"Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma","volume":"21","author":"Toyokawa","year":"2009","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102971_b0320","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12957-016-1081-4","article-title":"Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer","volume":"15","author":"Inokuchi","year":"2017","journal-title":"World J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102971_b0325","first-page":"1853","article-title":"Prognostic relevance of FGFR2 expression in stage II\/III gastric cancer with curative resection and S-1 chemotherapy","volume":"15","author":"Hosoda","year":"2018","journal-title":"Oncol Lett"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102971_b0330","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3892\/mco.2014.293","article-title":"Prognostic significance of the co\u2011overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer","volume":"2","author":"Murase","year":"2014","journal-title":"Mol Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102971_b0335","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00384-022-04162-2","article-title":"Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study","volume":"37","author":"Yasui","year":"2022","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.ctrv.2025.102971_b0340","doi-asserted-by":"crossref","unstructured":"Deshpande AM, Palencia S, Bellovin DI, Gemo AT, Giese T, Stohr B, et al. Expression of FGFR2b in gastric cancer as measured by immunohistochemistry with a highly specific monoclonal antibody. Presented at: American Association for Cancer Research; October 1, 2014; New Orleans, LA, USA.","DOI":"10.1158\/1538-7445.AM2014-2845"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102971_b0345","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10120-014-0360-4","article-title":"Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma","volume":"18","author":"Nagatsuma","year":"2015","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102971_b0350","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7150\/jca.28204","article-title":"Pathological and prognostic impacts of FGFR2 overexpression in gastric cancer: a meta-analysis","volume":"10","author":"Kim","year":"2019","journal-title":"J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102971_b0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264011","article-title":"FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort","volume":"17","author":"Schrumpf","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102971_b0360","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102971_b0365","doi-asserted-by":"crossref","first-page":"40","DOI":"10.17116\/patol20238503140","article-title":"Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization","volume":"85","author":"Raskin","year":"2023","journal-title":"Russ J Arch Pathol"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2025.102971_b0370","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2023.41.4_suppl.301","article-title":"Agreement between FGFR2 immunohistochemistry assays and fluorescence in situ hybridization (FISH) in metastatic gastric cancer: a comparison study","volume":"41","author":"Raskin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2025.102971_b0375","doi-asserted-by":"crossref","first-page":"19748","DOI":"10.18632\/oncotarget.7782","article-title":"Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma","volume":"7","author":"Tokunaga","year":"2016","journal-title":"Oncotarget"},{"issue":"12_suppl","key":"10.1016\/j.ctrv.2025.102971_b0380","doi-asserted-by":"crossref","first-page":"A033","DOI":"10.1158\/1535-7163.TARG-19-A033","article-title":"Abstract A033: Evaluation of FGFR2b in context of relevant biomarkers supports potential combination of anti-FGFR2b with anti-PD-(L)1 therapy in gastric cancer","volume":"18","author":"Sharma","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2025.102971_b0385","doi-asserted-by":"crossref","first-page":"S885","DOI":"10.1016\/j.annonc.2024.08.1486","article-title":"1420P Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC\/GEJC)","volume":"35","author":"Sato","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102971_b0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143207","article-title":"Intra-tumoral heterogeneity of HER2, FGFR2, cMET and ATM in gastric cancer: optimizing personalized healthcare through innovative pathological and statistical analysis","volume":"10","author":"Ye","year":"2015","journal-title":"PLoS One"},{"issue":"02","key":"10.1016\/j.ctrv.2025.102971_b0395","doi-asserted-by":"crossref","first-page":"E165","DOI":"10.1055\/s-0034-1391359","article-title":"Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer","volume":"03","author":"Gullo","year":"2015","journal-title":"Endosc Int Open"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102971_b0400","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","article-title":"Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases","volume":"121","author":"Coati","year":"2019","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102971_b0405","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41416-019-0515-5","article-title":"Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?","volume":"121","author":"Yamashita","year":"2019","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102971_b0410","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1634\/theoncologist.2015-0114","article-title":"Molecular testing for treatment of metastatic non-small cell lung cancer: how to implement evidence-based recommendations","volume":"20","author":"Levy","year":"2015","journal-title":"Oncologist"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:51:33Z","timestamp":1755499893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":82,"alternative-id":["S0305737225000933"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102971","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102971"}}